Table 2.
| Name | Type of Therapy/Vector | Function | Approval from | Year of Approval |
|---|---|---|---|---|
| GlyberaR | Adeno-associated virus based | Familial lipoprotein lipase deficiency | European Medicines Agency (EMA) | 2012 |
| IMLYGICR | Genetically modified herpes simplex virus type 1 |
Local treatment of unresectable lesions in patients with melanoma, | US Food and Drug Administration (FDA) | 2015 |
| StrimvelisR | γ-retrovirus-based therapy |
Treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) |
European Medicines Agency (EMA) | 2016 |
| KYMRIAHR | CD19-directed genetically modified autologous CAR T cell immunotherapies |
1—Treatment of non-Hodgkin lymphoma 2—Treatment of acute lymphoblastic leukaemia. |
US Food and Drug Administration (FDA) | 2017 |
| YESCARTAR | CD19-directed genetically modified autologous CAR T cell immunotherapies |
Treatment of non-Hodgkin lymphoma |
US Food and Drug Administration (FDA) | 2017 |
| LUXTURNAR | AAV-based gene therapy | Treatment of biallelic RPE65 mutation-associated retinal dystrophy. |
US Food and Drug Administration (FDA) | 2017 |